Compare USNA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | PCRX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 1.0B |
| IPO Year | 1996 | 2011 |
| Metric | USNA | PCRX |
|---|---|---|
| Price | $20.31 | $26.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $36.00 | $32.86 |
| AVG Volume (30 Days) | 173.0K | ★ 723.2K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | 0.47 |
| Revenue | ★ $912,670,000.00 | $716,791,000.00 |
| Revenue This Year | $9.87 | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ $22.73 | $55.78 |
| Revenue Growth | ★ 5.88 | 3.14 |
| 52 Week Low | $18.48 | $18.17 |
| 52 Week High | $38.32 | $27.64 |
| Indicator | USNA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 73.86 |
| Support Level | $19.33 | $25.17 |
| Resistance Level | $21.11 | $24.81 |
| Average True Range (ATR) | 0.60 | 0.94 |
| MACD | 0.22 | 0.28 |
| Stochastic Oscillator | 57.02 | 89.16 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.